Trial Profile
A Phase 1/2a Open-Label Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells) Into Subjects With Transverse Myelitis (TM)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Human glial restricted progenitor cells based therapeutics (Primary)
- Indications Transverse myelitis
- Focus Adverse reactions; First in man
- Sponsors Q Therapeutics
- 17 Aug 2023 Planned End Date changed from 1 Jun 2024 to 1 Dec 2024.
- 17 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jul 2024.
- 17 Aug 2023 Status changed from not yet recruiting to recruiting.